Key facts
- This page summarizes Rupert D'Souza's Form 4 filing for Adverum Biotechnologies, Inc. (ADVM).
- 2 reported transactions and 0 derivative rows are listed below.
- Accepted by SEC: 17 May 2022, 18:28.
Rupert D'Souza - 13 May 2022 Form 4 Insider Report for Adverum Biotechnologies, Inc. (ADVM)
- Reporting relationship
- Chief Financial Officer
- Issuer ticker
- ADVM
- Reported as of
- 13 May 2022
- Net transaction value
- +$16,857
- SEC form
- 4
- Accepted by SEC
- 17 May 2022, 18:28:44 UTC
- Prior SEC filing
- 08 Dec 2021
- Source filing
- View source filing
- Reporting owner signature
- Rupert D'Souza, by /s/ Ron A. Metzger, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Rupert D'Souza filed Form 4 for Adverum Biotechnologies, Inc. (ADVM) on 17 May 2022.
Change
- Previous filing in this sequence was filed on 08 Dec 2021.
- Current net transaction value: +$16,857.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ADVM
transaction
Common Stock
Purchase
- Transaction value
- $8,585
- Shares
- +10,000
- Change %
- +1176%
- Price
- $0.8585
- Shares after
- 10,850
- Date
- 13 May 2022
- Ownership
- Direct
- Footnotes
- F1
ADVM
transaction
Common Stock
Purchase
- Transaction value
- $8,272
- Shares
- +10,000
- Change %
- +92%
- Price
- $0.8272
- Shares after
- 20,850
- Date
- 17 May 2022
- Ownership
- Direct
- Footnotes
- F2
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 2 footnotes
Footnote F1
Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $0.856 to $0.865. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.
Footnote F2
Price reported is a weighted-average purchase price. The shares were purchased at prices ranging from $0.8245 to $0.828. The reporting person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares purchased at each separate price.